Investment Type

Product Portfolio Acquired by Essential Pharma

Date

December 2021

Location

Egham, UK

Sector

Healthcare

Industries

Pharmaceuticals

About Novartis

Essential Pharma significantly expands its Global Portfolio with product acquisitions for ocular and postpartum therapies from world leading pharmaceutical company, Novartis

Essential Pharma, acquired two new therapeutic areas to the business – ophthalmology and emergency obstetric medicine – with the acquisitions of the worldwide rights (excluding US and India) to two clinically well-established products from Novartis. The products are sold in over 50 countries worldwide, and their acquisition brings significant expansion to Essential Pharma’s portfolio as the company executes on its global growth ambitions.